SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-016887
Filing Date
2022-08-11
Accepted
2022-08-11 16:17:48
Documents
13
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K antx-20220811.htm   iXBRL 8-K 54802
2 EX-99.1 antx-ex99_1.htm EX-99.1 164456
  Complete submission text file 0000950170-22-016887.txt   350429

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT antx-20220811_lab.xml EX-101.LAB 14110
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT antx-20220811.xsd EX-101.SCH 2516
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT antx-20220811_pre.xml EX-101.PRE 10401
7 EXTRACTED XBRL INSTANCE DOCUMENT antx-20220811_htm.xml XML 4913
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 221156131
SIC: 2834 Pharmaceutical Preparations